Canadian Online Pharmacy

CDER New February 11, 2014

FDA (U.S. Food and Drug Administration)

What's New on the FDA Drugs Site

February 10, 2014 


New and Generic Drug Approvals

February 9, 2014

Drug NameActive IngredientDosage Form/RouteSponsorSubmission Type
Vivitrol naltrexone For Suspension, Extended Release;Intramuscular Alkermes Manufacturing Change or Addition

 

February 7, 2014

Drug NameActive IngredientDosage Form/RouteSponsorSubmission Type
Agrylin anagrelide hydrochloride Capsule;Oral Shire Llc Labeling Revision
Ammonia N 13 ammonia n-13 Injectable;Intravenous Wa Univ Sch Med Approval
Buspirone Hydrochloride buspirone hydrochloride Tablet;Oral Zydus Pharms Usa Inc Approval
Ceftriaxone and Dextrose In Duplex Container ceftriaxone sodium Injectable;Injection B Braun Manufacturing Change or Addition
Ethamolin ethanolamine oleate Injectable;Injection Qol Medcl Manufacturing Change or Addition
Ozurdex dexamethasone Implant;Intravitreal Allergan Labeling Revision
Ritalin methylphenidate hydrochloride Tablet;Oral Novartis Manufacturing Change or Addition
Vibativ telavancin hydrochloride Powder;Iv (Infusion) Theravance Inc Labeling Revision
Victrelis boceprevir Capsule;Oral Merck Sharp Dohme Labeling Revision
Zoledronic Acid zoledronic acid Injectable;Iv (Infusion) Acs Dobfar Info Sa Manufacturing Change or Addition
Zytiga abiraterone acetate Tablet;Oral Janssen Biotech Manufacturing Change or Addition

 


This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery